Asthma and COPD Medicines Market Size Report 2025
On Oct 29, the latest report "Global Asthma and COPD Medicines Market 2025 by Manufacturers, Regions, Types and Applications, Forecast to 2031" from Global Info Research provides a detailed and comprehensive analysis of the global Asthma and COPD Medicines market. The report provides both quantitative and qualitative analysis by manufacturers, regions and countries, types and applications. As the market is constantly changing, this report explores market competition, supply and demand trends, and key factors that are causing many market demand changes. The report also provides company profiles and product examples of some of the competitors, as well as market share estimates for some of the leading players in 2025.
Get Report Sample with Industry Insights https://www.globalinforesearch.com/reports/2953242/asthma-and-copd-medicines
According to our (Global Info Research) latest study, the global Asthma and COPD Medicines market size was valued at US$ 12927 million in 2024 and is forecast to a readjusted size of USD 16809 million by 2031 with a CAGR of 3.8% during review period.
In this report, we will assess the current U.S. tariff framework alongside international policy adaptations, analyzing their effects on competitive market structures, regional economic dynamics, and supply chain resilience.
Asthma and Chronic Obstructive Pulmonary Disease (COPD) medicines primarily include inhaled corticosteroids (ICS), long-acting beta-2 agonists (LABA), long-acting muscarinic antagonists (LAMA), and fixed-dose combination therapies. The upstream supply chain relies on active pharmaceutical ingredients (APIs), inhalation devices such as dry powder inhalers and metered-dose inhalers, and pharmaceutical excipients. Leading global suppliers and contract manufacturers such as Catalent, Lonza, Recipharm, and Hovione play critical roles in API production, inhalation formulation development, and device manufacturing, ensuring product efficacy and stability.
Downstream, key customers include major hospitals, respiratory specialty clinics, retail pharmacies, and digital healthcare platforms. The core patient base is composed of individuals suffering from chronic respiratory diseases, with demand growing steadily in regions facing aging populations and higher air pollution levels. Global pharmaceutical leaders such as GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, and Novartis dominate the sector, leveraging innovative drug pipelines and extensive distribution networks, while regional pharmaceutical firms expand their presence through generics and localized market strategies.
In 2024, the global average price of asthma and chronic obstructive pulmonary disease (COPD) medicines is approximately USD 18.6 per unit, with total sales reaching around 675 million units.
This report is a detailed and comprehensive analysis for global Asthma and COPD Medicines market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approval.
Asthma and COPD Medicines market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type: Quick Reliever Medicines、 Maintenance/Controller Medicines、 Others
Market segment by Application: Hospital、 Clinic、 Others
Major players covered: Boehringer Ingelheim、 GSK、 Teva Pharmaceutical、 Prasco Laboratories、 Cipla、 Lupin Laboratories、 Laboratorio Aldo-Union、 Polpharma、 Novartis、 The Menarini Group、 Covis Pharma、 Zentiva、 Alfasigma、 Gebro-Pharma、 Kohl Medical、 Sumitomo Pharma、 Chiesi Farmaceutici、 Glenmark Pharmaceuticals、 Orion Corporation、 Bausch Health、 Viatris、 AstraZeneca、 LEK-AM、 Adamed Group、 STADA Arzneimittel、 Organon、 Anhui Wellman Pharmaceutical、 Zhejiang Xianjun Pharmaceutical、 Chia Tai Tianqing Pharmaceutical Group、 Nanchang Helioeast Technology、 Jewim Pharmaceutical、 Heilongjiang Fulekang Pharmaceutical、 Shanghai Pharmaceuticals、 Lunan Better Pharmaceutical、 China Resources Double Crane Pharmaceutical
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Asthma and COPD Medicines product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Asthma and COPD Medicines, with price, sales quantity, revenue, and global market share of Asthma and COPD Medicines from 2020 to 2025.
Chapter 3, the Asthma and COPD Medicines competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Asthma and COPD Medicines breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment Asthma and COPD Medicines the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the Asthma and COPD Medicines sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2024.and Asthma and COPD Medicines market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Asthma and COPD Medicines.
Chapter 14 and 15, to describe Asthma and COPD Medicines sales channel, distributors, customers, research findings and conclusion.
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Asthma and COPD Medicines
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
Global Info Research is a company that digs deep into global industry information to support enterprises with market strategies and in-depth market development analysis reports. We provides market information consulting services in the global region to support enterprise strategic planning and official information reporting, and focuses on customized research, management consulting, IPO consulting, industry chain research, database and top industry services. At the same time, Global Info Research is also a report publisher, a customer and an interest-based suppliers, and is trusted by more than 30,000 companies around the world. We will always carry out all aspects of our business with excellent expertise and experience.
Contact Us:
Global Info Research
Web: https://www.globalinforesearch.com
Email: report@globalinforesearch.com
CN: 0086-176 6505 2062
HK: 00852-58030175
Get Report Sample with Industry Insights https://www.globalinforesearch.com/reports/2953242/asthma-and-copd-medicines
According to our (Global Info Research) latest study, the global Asthma and COPD Medicines market size was valued at US$ 12927 million in 2024 and is forecast to a readjusted size of USD 16809 million by 2031 with a CAGR of 3.8% during review period.
In this report, we will assess the current U.S. tariff framework alongside international policy adaptations, analyzing their effects on competitive market structures, regional economic dynamics, and supply chain resilience.
Asthma and Chronic Obstructive Pulmonary Disease (COPD) medicines primarily include inhaled corticosteroids (ICS), long-acting beta-2 agonists (LABA), long-acting muscarinic antagonists (LAMA), and fixed-dose combination therapies. The upstream supply chain relies on active pharmaceutical ingredients (APIs), inhalation devices such as dry powder inhalers and metered-dose inhalers, and pharmaceutical excipients. Leading global suppliers and contract manufacturers such as Catalent, Lonza, Recipharm, and Hovione play critical roles in API production, inhalation formulation development, and device manufacturing, ensuring product efficacy and stability.
Downstream, key customers include major hospitals, respiratory specialty clinics, retail pharmacies, and digital healthcare platforms. The core patient base is composed of individuals suffering from chronic respiratory diseases, with demand growing steadily in regions facing aging populations and higher air pollution levels. Global pharmaceutical leaders such as GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, and Novartis dominate the sector, leveraging innovative drug pipelines and extensive distribution networks, while regional pharmaceutical firms expand their presence through generics and localized market strategies.
In 2024, the global average price of asthma and chronic obstructive pulmonary disease (COPD) medicines is approximately USD 18.6 per unit, with total sales reaching around 675 million units.
This report is a detailed and comprehensive analysis for global Asthma and COPD Medicines market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approval.
Asthma and COPD Medicines market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type: Quick Reliever Medicines、 Maintenance/Controller Medicines、 Others
Market segment by Application: Hospital、 Clinic、 Others
Major players covered: Boehringer Ingelheim、 GSK、 Teva Pharmaceutical、 Prasco Laboratories、 Cipla、 Lupin Laboratories、 Laboratorio Aldo-Union、 Polpharma、 Novartis、 The Menarini Group、 Covis Pharma、 Zentiva、 Alfasigma、 Gebro-Pharma、 Kohl Medical、 Sumitomo Pharma、 Chiesi Farmaceutici、 Glenmark Pharmaceuticals、 Orion Corporation、 Bausch Health、 Viatris、 AstraZeneca、 LEK-AM、 Adamed Group、 STADA Arzneimittel、 Organon、 Anhui Wellman Pharmaceutical、 Zhejiang Xianjun Pharmaceutical、 Chia Tai Tianqing Pharmaceutical Group、 Nanchang Helioeast Technology、 Jewim Pharmaceutical、 Heilongjiang Fulekang Pharmaceutical、 Shanghai Pharmaceuticals、 Lunan Better Pharmaceutical、 China Resources Double Crane Pharmaceutical
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Asthma and COPD Medicines product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Asthma and COPD Medicines, with price, sales quantity, revenue, and global market share of Asthma and COPD Medicines from 2020 to 2025.
Chapter 3, the Asthma and COPD Medicines competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Asthma and COPD Medicines breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment Asthma and COPD Medicines the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the Asthma and COPD Medicines sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2024.and Asthma and COPD Medicines market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Asthma and COPD Medicines.
Chapter 14 and 15, to describe Asthma and COPD Medicines sales channel, distributors, customers, research findings and conclusion.
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Asthma and COPD Medicines
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
Global Info Research is a company that digs deep into global industry information to support enterprises with market strategies and in-depth market development analysis reports. We provides market information consulting services in the global region to support enterprise strategic planning and official information reporting, and focuses on customized research, management consulting, IPO consulting, industry chain research, database and top industry services. At the same time, Global Info Research is also a report publisher, a customer and an interest-based suppliers, and is trusted by more than 30,000 companies around the world. We will always carry out all aspects of our business with excellent expertise and experience.
Contact Us:
Global Info Research
Web: https://www.globalinforesearch.com
Email: report@globalinforesearch.com
CN: 0086-176 6505 2062
HK: 00852-58030175
